supCD7 CART
/ Institute of Hematology and Blood Diseases Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 04, 2025
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
(clinicaltrials.gov)
- P1/2 | N=12 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China
New P1/2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology
1 to 1
Of
1
Go to page
1